Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Mite mixture dose-ranging safety study in house dust mite allergic rhinitis
2014-002047-18Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Oct 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of house dust mite allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy (5 arms), sponsored by HAL Allergy Group. Started Oct 2014; status: completed.
02
Drugs
house dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2014-002047-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002047-18.